Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25005980 | 0.97 | LMNA (0.47) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL20747693 | 0.97 | LMNA (0.47) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL20747593 | 0.94 | LMNA (0.40) | LMNA | |
| SCHEMBL20747623 | 0.91 | LMNA (0.45) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL22951492 | 0.90 | LMNA (0.36) | LMNA | |
| SCHEMBL20747618 | 0.84 | LMNA (0.47) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL20747655 | 0.84 | LMNA (0.40) | LMNA | |
| SCHEMBL20747661 | 0.84 | LMNA (0.47) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL22955323 | 0.83 | MAPT (0.45) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL20747612 | 0.82 | MAPT (0.33) | LMNAMAPTMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | LMNA 2972/4885MAPT 3216/4885MEN1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.